Insulin-Based Versus Triple Oral Therapy for Newly Diagnosed Type 2 Diabetes
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Early use of insulin after diagnosis of type 2 diabetes is met with resistance because of associated weight gain, hypoglycemia, and fear of decreased compliance and quality of life (QoL). RESEARCH DESIGN AND METHODS: In treatment-naive patients with newly diagnosed type 2 diabetes, insulin and metformin were initiated for a 3-month lead-in period, then patients were randomly assigned to insulin and metformin (insulin group) or metformin, pioglitazone, and glyburide (oral group) for 36 months. Hypoglycemic events, compliance, A1C, weight, QoL, and treatment satisfaction were assessed. RESULTS: Of 29 patients randomly assigned into each group, 83% (insulin group) and 72% (oral group) completed this 3-year study. At study completion, A1C was 6.1 ± 0.6% (insulin group) versus 6.0 ± 0.8% (oral group). Weight increased similarly in both groups (P = 0.09) by 4.47 kg (95% CI 0.89–8.04 kg) (insulin group) and 7.15 kg (95% CI 4.18–10.13 kg) (orals group). Hypoglycemic events did not differ between groups (mild 0.51 event/person-month in the insulin group vs. 0.68 event/person-month in the orals group, P = 0.18 and severe 0.04 event/person-year in the insulin group vs. 0.09 event/person-year in the orals group, P = 0.53). Compliance, QoL, and treatment satisfaction were similar between groups, with 100% of patients randomly assigned to insulin willing to continue such treatment. CONCLUSIONS: When compared with a clinically equivalent treatment regimen, insulin-based therapy is effective and did not cause greater weight gain or hypoglycemia nor decrease compliance, treatment satisfaction, or QoL. Insulin is safe, well-accepted, and effective for ongoing treatment of patients with newly diagnosed type 2 diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2009) · Diabetes Care · doi:10.2337/dc08-9025 · Cited by 3,834
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy
Kahn, S. E., Haffner, S. M., Heise, M. A., Herman, W. H., Holman, R. R., Jones, N. P., Kravitz, B. G., Lachin, J. M., O'Neill, M. C., Zinman, B., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa066224 · Cited by 2,962
U.K. Prospective Diabetes Study Group (1995) · Diabetes · doi:10.2337/diab.44.11.1249 · Cited by 1,923
Ilkova, H., Glaser, B., Tunçkale, A., Bagriaçik, N., & Cerasi, E. (1997) · Diabetes Care · doi:10.2337/diacare.20.9.1353 · Cited by 269 · cited 1×
“Studies suggest that short-term treatment with insulin following diagnosis (15) or at time of “secondary drug failure” (16) improves betacell function and metabolic control.”
BackgroundHerman, W. H., Ilag, L. L., Johnson, S. L., Martin, C. L., Sinding, J., Al Harthi, A., Plunkett, C. D., LaPorte, F. B., Burke, R., Brown, M. B., et al. (2005) · Diabetes Care · doi:10.2337/diacare.28.7.1568 · Cited by 265
Self-citationSchwartz, S., Sievers, R., Strange, P., Lyness, W. H., Hollander, P., & For The INS-2061 Study Team (2003) · Diabetes Care · doi:10.2337/diacare.26.8.2238 · Cited by 117 · cited 1×
“When an insulin and metformin treatment regimen was compared to addition of a third oral hypoglycemic agent after failure of two oral agents, patients with triple oral therapy were less likely to complete the regimen due to lack of efficacy or intolerable side effects (14).”
Background
Cited by
Abdul‐Ghani, M. A., Puckett, C., Triplitt, C., Maggs, D., Adams, J., Cersosimo, E., & DeFronzo, R. A. (2015) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12417 · Cited by 208
Facilitating Healthy Coping in Patients With Diabetes: A Systematic Review
Thorpe, C. T., Fahey, L. E., Johnson, H., Deshpande, M., Thorpe, J. M., & Fisher, E. B. (2013) · The Diabetes Educator · doi:10.1177/0145721712464400 · Cited by 155
Clifford, S., Perez-Nieves, M., Skalicky, A. M., Reaney, M., & Coyne, K. S. (2014) · Current Medical Research and Opinion · doi:10.1185/03007995.2014.884491 · Cited by 99
Barriers to achieving glycemic targets: who omits insulin and why?
Weinger, K., & Beverly, E. A. (2010) · Diabetes Care · doi:10.2337/dc09-2132 · Cited by 53
Abdul‐Ghani, M., Migahid, O., Megahed, A., DeFronzo, R. A., Al‐Ozairi, E., & Jayyousi, A. (2020) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14153 · Cited by 21
Metadata
- Authors
- Lingvay, I., Legendre, J. L., Kaloyanova, P. F., Zhang, S., Adams-Huet, B., & Raskin, P.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2009-07-10
- Volume
- 32
- Issue
- 10
- Pages
- 1789-1795
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2095855723
- Cited by
- 94
- References
- 6
- FWCI
- 7.61
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.